Attached files
file | filename |
---|---|
EX-31 - EX-31 - Eidos Therapeutics, Inc. | eidx-ex31_8.htm |
EX-23.1 - EX-23.1 - Eidos Therapeutics, Inc. | eidx-ex231_10.htm |
EX-4.5 - EX-4.5 - Eidos Therapeutics, Inc. | eidx-ex45_957.htm |
10-K - 10-K - Eidos Therapeutics, Inc. | eidx-10k_20191231.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Eidos Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based upon my knowledge:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: February 26, 2020 |
|
By: |
/s/ Neil Kumar |
|
|
|
Neil Kumar |
|
|
|
Chief Executive Officer and Director (Principal Executive Officer and Principal Financial Officer) |